Evaluación económica de la utilización de hierro carboximaltosa en pacientes con deficiencia de hierro e insuficiencia cardiaca crónica en España

Comín‐Colet, Josep; Rubio-Rodríguez, Darío; Rubio-Terrés, Carlos; Enjuanes-Grau, Cristina; Gutzwiller, F; Anker, Stefan D.; Ponikowski, Piotr

doi:10.1016/j.recesp.2014.10.011

Cited by 20 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Analysis of the BI and cost-effectiveness of clinical interventions is an essential part of health technology assessment to support decision-making 31 . The Cost Effectiveness Analysis (CEA) of FCM in the SNHS was previously analysed by Comin-Colet et al 21 , who found that FCM in patients with CHF and ID was a cost-effective option with a cost of e6,123.78 per QALY (quality-adjusted life-year), and below the recommended threshold of e25,000 per QALY in Spain 32 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain

Delgado

Oliva

González-Franco

et al. 2020

Journal of Medical Economics

Self Cite

View full text Add to dashboard Cite

Objective: The treatment of iron deficiency (ID) with ferric carboxymaltose (FCM) improves the functional class and quality of life of chronic heart failure (CHF) patients with reduced left ventricular ejection fraction (LVEF), and reduces the rate of hospitalization due to worsening CHF. This study aims to evaluate the budget impact for the Spanish National Health System (SNHS) of treating ID in reduced LVEF CHF with FCM compared to non-iron treatment. Methods: We simulated a hypothetical cohort of 1000 CHF patients with ID and reduced LVEF based on the Spanish population characteristics. A decision-analytic model was also built using the data from the largest FCM clinical trial (CONFIRM-HF) that lasted for a year. We considered the use of healthcare resources from a national prospective study. A deterministic sensitivity analysis was carried out varying the corresponding baseline data by ±25%. Results: The cost of treating the simulated population with FCM was e2,570,914, while that of the non-iron treatment was e3,105,711, which corresponds to a cost saving of e534,797 per 1,000 patients in one year. Cost savings were mainly due to a decrease in the number of hospitalizations. All sensitivity analysis showed cost savings for the SNHS. Conclusions: FCM results in an annual cost saving of e534.80 per patient, and would thus be expected to reduce the economic burden of CHF in Spain.

show abstract

Section: Discussionmentioning

confidence: 99%

“…From an economic perspective, a 2015 study assessed the cost-effectiveness (CE) of using FCM in Spain for CHF with ID and reduced LVEF 21 . However, there is no information for the Spanish public healthcare setting about the (BI) of such treatment, i.e.…”

Section: Introductionmentioning

confidence: 99%

Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain

Delgado

Oliva

González-Franco

et al. 2020

Journal of Medical Economics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Sin embargo existen varios estudios de costo eficacia que demuestran que esta formulación es costo beneficiosa, considerando que se puede administrar mayor cantidad de hierro en cada administración, con un volumen de dilución menor que las otras presentaciones, y con menores efectos adversos de tipo de reacciones anafilácticas. (43) e) ¿Cómo se calcula la dosis de hierro y cómo se controla?…”

Section: C) ¿Cómo Hacemos Diagnóstico Del Déficit De Hierro?unclassified

Déficit de Hierro en Insuficiencia Cardíaca: Un Nuevo Horizonte Terapéutico

Papadópulos¹,

Araque²,

Gorricho³

2023

Rev. urug. med. interna

View full text Add to dashboard Cite

La Insuficiencia Cardíaca (IC) es un síndrome clínico complejo en el que convergen múltiples comorbilidades que deben ser abordadas y tratadas de una manera holística, lo que redunda en resultados favorables en términos de morbimortalidad. El déficit de hierro es una más de estas comorbilidades a las que nos enfrentan estos pacientes, teniendo un papel clave en su fisiopatología. Se recomienda su detección de forma sistemática y su seguimiento con el fin de realizar un tratamiento con hierro suplementario en forma oportuna y óptima con el fin de mejorar la calidad de vida de los pacientes, su deterioro funcional, con la consiguiente mejora en morbimortalidad y reingresos hospitalarios. Se presenta una revisión clínica de los aspectos más relevantes del concepto de déficit de hierro en Insuficiencia Cardíaca asi como su abordaje diagnóstico y de tratamiento.

show abstract

A budget impact analysis of iron polymaltose and ferric carboxymaltose infusions

2021

View full text Add to dashboard Cite

Objective: To compare the direct costs of ferric carboxymaltose (FCM) infusions, and iron polymaltose (IPM) infused via either a slow or rapid infusion; and explore potential savings associated with increased uptake of the least-expensive option at a local hospital. Setting: Hospital staff responsible for manufacturing, administering, and monitoring iron infusions, and the patients that received them at the Royal Hobart Hospital in 2018.Method: Frequency analysis identi ed the most prescribed iron infusion doses. A time-motion methodology was used to calculate the direct costs for each protocol at these doses. Finally, a budget-impact analysis of encouraging increased use of the least-expensive infusion protocol was conducted.Main outcome measures: Total direct costs for each infusion protocol at common doses. Potential budget savings associated with switching to the lowest costing of these infusion protocols where possible.Results: The most common doses were 0.5g, 1g, 1.5g and 2g. At these dose points, FCM infusions are the least expensive, but only if national health subsidies are applied. In cases where they do not apply, IPM prepared from ampoules and infused using the rapid protocol ('IPM Ampoules Rapid') is the least expensive. Switching all applicable FCM infusions and IPM infusions administered using the slow infusion protocol to IPM Ampoules Rapid is projected to yield up to $12,000 worth of savings annually.Conclusions: Increased use of the IPM Ampoules Rapid protocol when government-subsidised options are not available is projected to have cost-saving outcomes. Investigation of implementation strategies to increase the use of this protocol are warranted. Impacts On PracticeThis study demonstrates the total direct costs of both the FCM and IPM infused via either a slow or rapid infusion protocol. While there has been a number of studies outlining the safety and e cacy of these infusion protocols, their cost implications have not been fully investigated previously.Amidst the increasing use of intravenous iron, this study outlines which is the overall lowest costing iron infusion protocol, identifying factors contributing to this (e.g. different dose points, health subsidies) and the potential associated costs savings with promoting increased use of lower-costing protocols. Effort should be made to be exible in using the most cost-optimal infusion protocol in different scenarios, whilst also maintaining safety. Interventions to increase the use of lower-costing infusion protocols should be explored.

show abstract

Evaluación económica de la utilización de hierro carboximaltosa en pacientes con deficiencia de hierro e insuficiencia cardiaca crónica en España

Cited by 20 publications

References 19 publications

Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain

Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain

Déficit de Hierro en Insuficiencia Cardíaca: Un Nuevo Horizonte Terapéutico

A budget impact analysis of iron polymaltose and ferric carboxymaltose infusions

Contact Info

Product

Resources

About